- Home
- OPCH vs VERA Comparison
OPCH vs VERA Comparison
Compare OPCH & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | VERA |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPCH | VERA |
|---|---|---|
| Price | $21.63 | $37.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $36.57 | ★ $81.30 |
| AVG Volume (30 Days) | 2.3M | ★ 2.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,998,202,000.00 | N/A |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $8.55 | $472.48 |
| P/E Ratio | $75.00 | ★ N/A |
| Revenue Growth | ★ 16.17 | N/A |
| 52 Week Low | $18.01 | $19.07 |
| 52 Week High | $36.80 | $56.05 |
Technical Indicators
Market Signals| Indicator | OPCH | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 42.34 |
| Support Level | $20.82 | $32.48 |
| Resistance Level | $22.42 | $38.59 |
| Average True Range (ATR) | 0.61 | 2.75 |
| MACD | 0.04 | -0.78 |
| Stochastic Oscillator | 44.88 | 11.67 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.